ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Stock Information for Evoke Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evoke Pharma Inc.

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT"
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
ImmunoPrecise Releases New Findings Showing LENSai(TM) Quickly Flags Anti-Drug-Antibody Risk-Long Before the Clinic
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.